Clinical Trials List
Protocol NumberKN035-CN-006
2023-01-01 - 2023-12-31
Phase II
Terminated2
-
Trial Applicant
Orient EuroPharma Co., Ltd.
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2025/08/19
Investigators and Locations
Co-Principal Investigator
- 林正耀 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 林建良 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 曹朝榮 Division of Hematology & Oncology
- 蕭聖諺 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- YU-YUN SHAO Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
- 陳國興 Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- JHE-CYUAN GUO Division of Hematology & Oncology
- TSUNG-HAO LIU Division of Hematology & Oncology
- 李佳真 Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- Chiun Hsu Division of Hematology & Oncology
- 黃柏翔 Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- 梁逸歆 Division of Hematology & Oncology
- SUNG-HSIN KUO Division of Hematology & Oncology
- Ann-Lii Cheng Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
200 participants
-
Global
2000 participants
